Evoke Pharma (Evoke Pharma) Change In Receivables : $-0.05 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Evoke Pharma Change In Receivables?

Evoke Pharma's change in receivables for the quarter that ended in Dec. 2023 was $0.56 Mil. It means Evoke Pharma's Accounts Receivable declined by $0.56 Mil from Sep. 2023 to Dec. 2023 .

Evoke Pharma's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.05 Mil. It means Evoke Pharma's Accounts Receivable increased by $0.05 Mil from Dec. 2022 to Dec. 2023 .

Evoke Pharma's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.67 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Evoke Pharma's Days Sales Outstanding for the three months ended in Dec. 2023 was 36.64.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Evoke Pharma's liquidation value for the three months ended in Dec. 2023 was $-4.16 Mil.

Evoke Pharma Change In Receivables Historical Data

The historical data trend for Evoke Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma Change In Receivables Chart

Evoke Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.27

-0.33

-0.05

Evoke Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															0.05	-0.06	-0.34	-0.21	0.56

Evoke Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05 Mil.

Evoke Pharma (NAS:EVOK) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Evoke Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.673	/	1.676	*	91
=	36.64

2. In Ben Graham's calculation of liquidation value, Evoke Pharma's accounts receivable are only considered to be worth 75% of book value:

Evoke Pharma's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4.739	-	9.648	+	0.75 * 0.673	+	0.5 * 0.482
=	-4.16

Evoke Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Evoke Pharma (Evoke Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (NAS:EVOK) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

EV00:Germany

Address

420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075

Website

https://www.evokepharma.com

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Executives

Vickie S Reed	director	TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David A Gonyer	director, officer: President and CEO	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Matthew J D'onofrio	officer: Exec VP, Chief Bus. Officer	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Lvp Gp Iii, Llc	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Kenneth J Widder	director, 10 percent owner	10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Dp Vii Associates Lp	10 percent owner	ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Domain Parters Vii L P	10 percent owner	ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Nimesh Shah	10 percent owner	12481 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO CA 92130
Marilyn R. Carlson	officer: Chief Medical Officer	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Todd C Brady	director	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Scott L Glenn	director
Lvpmc, Llc	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Partners Lp	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Associates, L.p.	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111